Evidence map›Paper›PMID 42718658›Full record

ArticleFrontiers in cellular and infection microbiology2026

NLRC4 and NLRP3 in tissues as potential biomarkers for the diagnosis of non-small cell lung cancer in pulmonary tuberculosis.

Zetian Zhang, Zhikai Zhao, Shuanshuan Xie, Boyu Guo, Chenlei Cai, Chunyan Wu, Xiaohui Hao, Jian Ni, Haiyan Cui, Mengting Xiong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zetian Zhang *Clinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhikai Zhao *Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine,Tongji University, Shanghai, China.
Shuanshuan Xie *Department of Respiratory Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Boyu GuoDepartment of Respiratory Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Chenlei CaiDepartment of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Chunyan WuDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine,Tongji University, Shanghai, China.
Xiaohui HaoClinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Jian NiDepartment of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Haiyan CuiClinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Mengting XiongClinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Distinguishing non-small lung cancer (NSCLC) with tuberculosis from pulmonary tuberculosis (PTB) is still a major clinical problem. Misdiagnosis or missed diagnosis can lead to missed opportunities for optimal treatment, making highly sensitive diagnostic criteria crucial. Methods: Database analysis and histological analysis were used at the same time. A total of 55 patients were included in the histological analysis, including 20 patients with both NSCLC and PTB (NSCLC-PTB group), 20 patients with NSCLC alone (NSCLC group), and 15 patients with PTB alone (PTB group). The levels of NLRC4 and NLRP3 in each sample were analysed using the optical density method. Statistical analyses were performed, including the LIMMA algorithm, regression, and ROC analysis, to assess biomarker levels and their correlation with clinical outcomes. Results: The expression of NLRC4 and NLRP3 was significantly down-regulated in NSCLC tissues (both P < 0.001), and low expression of NLRC4 was associated with shorter overall survival (HR = 0.76, P < 0.001), while low expression of NLRP3 was associated with longer survival (HR = 1.21, P < 0.001). The level of NLRC4 in cancer nodules in the NSCLC-PTB group was significantly lower than that in the PTB group (0.0177 ± 0.0218 vs. 0.0299 ± 0.0117, Conclusion: The use of NLRC4 and NLRP3 as biomarkers can improve the certainty of NSCLC prediction and has great prospects.

Indexed as

Calcium-Binding ProteinsCarcinoma, Non-Small-Cell LungCARD Signaling Adaptor ProteinsLung NeoplasmsNLR Family, Pyrin Domain-Containing 3 ProteinTuberculosis, PulmonaryAdultAgedBiomarkersBiomarkers, TumorFemaleHumansMaleMiddle AgedBiomarkersBiomarkers, TumorCalcium-Binding ProteinsCARD Signaling Adaptor ProteinsNLRC4 protein, humanNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanbiomarkersNLRC4NLRP3non-small lung cancerpulmonary tuberculosis

Identifiers

PMID42718658
PMCPMC13553391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.